Ozempic vs Zepbound 2026: Diabetes vs Weight Loss
Ozempic is FDA-approved for type 2 diabetes management, while Zepbound is FDA-approved specifically for weight loss in adults with obesity or overweight with weight-related conditions. Both contain semaglutide but are marketed, dosed, and indicated for different primary purposes.
Ozempic (semaglutide)
Weekly injectable GLP-1 receptor agonist for type 2 diabetes with potent weight loss and cardiovascular benefits.
Patients with type 2 diabetes seeking to improve blood sugar control and reduce cardiovascular risk
Zepbound (semaglutide)
GLP-1 receptor agonist injection for chronic weight management approved by FDA in 2023.
Adults with BMI ≥30 or BMI ≥27 with weight-related conditions who prioritize weight loss
Quick Answer
AI SummaryOzempic is FDA-approved for type 2 diabetes management, while Zepbound is FDA-approved specifically for weight loss in adults with obesity or overweight with weight-related conditions. Both contain semaglutide but are marketed, dosed, and indicated for different primary purposes.
Our Verdict
AI-assistedChoose Ozempic if you have type 2 diabetes and need glycemic control—it's the established standard of care with robust cardiovascular benefits in diabetic populations. Choose Zepbound if your primary goal is weight loss and you don't have diabetes, as it's specifically optimized for weight management with higher maintenance doses and better insurance coverage for this indication.
Was this verdict helpful?
TIE — neck and neck
Choose Ozempic (semaglutide) if
Patients with type 2 diabetes seeking to improve blood sugar control and reduce cardiovascular risk
Choose Zepbound (semaglutide) if
Adults with BMI ≥30 or BMI ≥27 with weight-related conditions who prioritize weight loss
Track this comparison
Get notified when prices change, new specs ship, or our verdict updates.
Triggers: price change new spec verdict update
No spam. Stop anytime.
Key Differences at a Glance
- Primary FDA Indication:Type 2 diabetes management vs Chronic weight management
- Starting Dose:0.25 mg weekly vs 0.25 mg weekly
- Maximum Maintenance Dose:✓ Zepbound (semaglutide) wins(2.4 mg weekly vs 2.0 mg weekly)
Key Facts & Figures
26 numeric metrics compared
| Metric | Ozempic (semaglutide) | Zepbound (semaglutide) | Ratio |
|---|---|---|---|
| Dosing Frequency(times per week) | 1x weekly | — | — |
| Time to Maximum Dose(weeks) | 4 weeks | — | — |
| FDA Approval Year (for weight loss)(year) | 2021 (Wegovy) | — | — |
| Average Monthly Cost (Uninsured)(USD) | $1,100 | — | — |
| Clinical Trial Duration(weeks) | 68 weeks (STEP) | — | — |
| FDA Approval Year | 2017 | 2023 | |
| Maximum Weekly Dose(mg) | 2.0 mg | 2.4 mg | |
| HbA1c Reduction (Type 2 Diabetes)(%) | 1.5-1.8% | Not primary endpoint | — |
| Average Weight Loss in Pivotal Trial(lbs) | 4-6 lbs (secondary outcome) | 22 lbs | |
| Nausea Incidence Rate(%) | 25-40% | 44% | |
| Insurance Coverage Rate for Primary Indication(%) | 85% (diabetes) | 72% (weight loss) | |
| CVOT Cardiovascular Risk Reduction(%) | 26% | Not studied (non-diabetic population) | — |
| Trial Duration for Primary Endpoint(weeks) | 52 weeks (SUSTAIN-6) | 68 weeks (STEP trials) | |
| Maximum Weight Loss at Highest Approved Dose(%) | 22% | — | — |
| A1C Reduction (Average)(mmol/mol) | 1.5-1.8% | — | — |
| Half-Life Duration(hours) | 168 hours (7 days) | — | — |
| Average Monthly Cost (Without Insurance)(USD) | $1,100 | — | — |
| Time to Reach Steady State(weeks) | 4-5 weeks | — | — |
| GI Side Effect Incidence Rate(%) | 32% | — | — |
| Years on Market(years) | 11 years (since 2013) | — | — |
| Injection Frequency | Once weekly | — | — |
| Average Body Weight Loss(%) | 15% | — | — |
| Cardiovascular Event Reduction(%) | 26% (SUSTAIN-6) | — | — |
| Maximum Approved Dose(mg) | 2.4 mg weekly | — | — |
| Years Since FDA Approval(years) | 7 years (2017) | — | — |
| Nausea Incidence in Trials(%) | 25-39% | — | — |
Sourced from publicly available data ·
Key Differences
7 attributes compared head-to-head
- Type 2 diabetes managementPrimary FDA IndicationChronic weight management
- 0.25 mg weeklyStarting Dose0.25 mg weekly
- 2.0 mg weeklyMaximum Maintenance Dose2.4 mg weekly(winner)
- Not primary endpoint (avg 4-6 lbs in diabetes trials)Average Weight Loss (Clinical Trial)22 lbs over 68 weeks (15% body weight reduction)(winner)
- Rarely covered for weight loss onlyInsurance Coverage for Weight LossIncreasingly covered by insurers(winner)
- Type 2 diabetes patients (with or without obesity)Approved Patient PopulationBMI ≥30 kg/m² or BMI ≥27 with weight-related condition
- $900-1,100Average Monthly Cost (Without Insurance)$900-1,100
- Primary FDA Indication
Ozempic (semaglutide)
Type 2 diabetes management
Zepbound (semaglutide)
Chronic weight management
- Starting Dose
Ozempic (semaglutide)
0.25 mg weekly
Zepbound (semaglutide)
0.25 mg weekly
- Maximum Maintenance Dose
Ozempic (semaglutide)
2.0 mg weekly
Zepbound (semaglutide)
2.4 mg weekly(winner)
- Average Weight Loss (Clinical Trial)
Ozempic (semaglutide)
Not primary endpoint (avg 4-6 lbs in diabetes trials)
Zepbound (semaglutide)
22 lbs over 68 weeks (15% body weight reduction)(winner)
- Insurance Coverage for Weight Loss
Ozempic (semaglutide)
Rarely covered for weight loss only
Zepbound (semaglutide)
Increasingly covered by insurers(winner)
- Approved Patient Population
Ozempic (semaglutide)
Type 2 diabetes patients (with or without obesity)
Zepbound (semaglutide)
BMI ≥30 kg/m² or BMI ≥27 with weight-related condition
- Average Monthly Cost (Without Insurance)
Ozempic (semaglutide)
$900-1,100
Zepbound (semaglutide)
$900-1,100
Full Comparison
| Attribute | Ozempic (semaglutide) | Zepbound (semaglutide) |
|---|---|---|
| Average Weight Loss(%) | 15% | — |
| Time to Maximum Dose(weeks) | 4 weeks | — |
| Maximum Weight Loss at Highest Approved Dose(%) | 22% | — |
| A1C Reduction (Average)(mmol/mol) | 1.5-1.8% | — |
| Average Body Weight Loss(%) | 15% | — |
| Dosing Frequency(times per week) | 1x weekly | — |
| FDA Approval Year (for weight loss)(year) | 2021 (Wegovy) | — |
| Average Monthly Cost (Uninsured)(USD) | $1,100 | — |
| Average Monthly Cost (Without Insurance)(USD) | $1,100 | — |
| Clinical Trial Duration(weeks) | 68 weeks (STEP) | — |
| FDA Approval Year | 2017(winner) | 2023 |
| Maximum Weekly Dose(mg) | 2.0 mg | 2.4 mg(winner) |
| Maximum Approved Dose(mg) | 2.4 mg weekly | — |
| HbA1c Reduction (Type 2 Diabetes)(%) | 1.5-1.8% | Not primary endpoint |
| Average Weight Loss in Pivotal Trial(lbs) | 4-6 lbs (secondary outcome) | 22 lbs(winner) |
| Nausea Incidence Rate(%) | 25-40%(winner) | 44% |
| GI Side Effect Incidence Rate(%) | 32% | — |
| Nausea Incidence in Trials(%) | 25-39% | — |
| Insurance Coverage Rate for Primary Indication(%) | 85% (diabetes)(winner) | 72% (weight loss) |
| CVOT Cardiovascular Risk Reduction(%) | 26% | Not studied (non-diabetic population) |
| Trial Duration for Primary Endpoint(weeks) | 52 weeks (SUSTAIN-6) | 68 weeks (STEP trials)(winner) |
| Half-Life Duration(hours) | 168 hours (7 days) | — |
| Time to Reach Steady State(weeks) | 4-5 weeks | — |
| Years on Market(years) | 11 years (since 2013) | — |
| Injection Frequency | Once weekly | — |
| Cardiovascular Event Reduction(%) | 26% (SUSTAIN-6) | — |
| Years Since FDA Approval(years) | 7 years (2017) | — |
Pros & Cons
10 pros·4 cons across both
Ozempic (semaglutide)
Pros
- Reduces HbA1c by 1.5-1.8% in type 2 diabetes patients
- Cardiovascular benefits: 26% reduction in major adverse cardiovascular events (CVOT trial)
- Established safety profile with 6+ years of real-world data
- Improves kidney disease markers in diabetic patients
- More likely to be covered by insurance for diabetes indication
Cons
- Maximum dose of 2.0 mg is lower than Zepbound, potentially limiting weight loss efficacy for non-diabetics
- Gastrointestinal side effects (nausea, vomiting) in 25-40% of users during titration
Zepbound (semaglutide)
Pros
- Higher maximum dose of 2.4 mg optimized for weight loss outcomes
- Average 15% body weight reduction (22 lbs over 68 weeks) in pivotal trial
- Increasingly covered by major insurers for weight loss indication
- Approved specifically for obesity/overweight with metabolic conditions
- Same active ingredient as Ozempic with identical safety mechanism
Cons
- Gastrointestinal side effects (nausea, vomiting, diarrhea) in up to 44% of users
- Newer indication (approved 2023) with less long-term real-world data compared to Ozempic
Frequently Asked Questions
5 questions
While Ozempic (semaglutide) does cause weight loss as a side effect, it is not FDA-approved for weight loss alone. Off-label use for weight loss is occurring but is not the intended indication. Zepbound is the FDA-approved option specifically for weight management in non-diabetic patients. Some insurance plans will not cover Ozempic for weight loss specifically due to the indication mismatch.
Resources & Learn More
Curated sources to dive deeper
Where to Buy
As an affiliate, we may earn a commission from qualifying purchases at no extra cost to you. Learn more about our affiliate disclosure
Wikipedia
- W
Ozempic (semaglutide) on Wikipedia (opens in new tab)
Weekly injectable GLP-1 receptor agonist for type 2 diabetes with potent weight loss and cardiovascular benefits.
- W
Zepbound (semaglutide) on Wikipedia (opens in new tab)
GLP-1 receptor agonist injection for chronic weight management approved by FDA in 2023.
Related Comparisons
12 more to explore
Ozempic vs Saxenda
healthOzempic vs Victoza
healthOzempic vs Victoza
healthYoga vs Pilates
healthIbuprofen vs Acetaminophen
healthInvisalign vs Traditional Braces
healthWhey Protein vs Casein Protein
healthCrossFit vs Gym Training
healthFlu Shot vs COVID Vaccine
healthOrganic Food vs Non-Organic Food
healthTherapy vs Medication
healthMeditation vs Yoga
health
Related Articles
1 article
Explore More
Related comparisons and categories